Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617.
An 81-year-old castrate-resistant prostate cancer man with multiple lymph node, bone, and hepatic metastases received four cycles of Lu-PSMA-617 treatments at our department from May to December 2015. All of his liver metastases showed PSMA expression in Ga-PSMA PET performed before the first cycle. Under this therapy, all of the metastases showed significant regression in size and PSMA expression over time.
From the *Department of Nuclear Medicine, University Hospital Bonn, Bonn; and †Private Office for Urology, Bonn, Germany.
Xiao
X
Wei
Carl
C
Schlenkhoff
Claudia
C
Sopora
Markus
M
Essler
Hojjat
H
Ahmadzadehfar
D000369:Aged, 80 and over; D004151:Dipeptides / Q000627:therapeutic use*; D006573:Heterocyclic Compounds, 1-Ring / Q000627:therapeutic use*; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000556:secondary; D008187:Lutetium; D008297:Male; D017430:Prostate-Specific Antigen; D064129:Prostatic Neoplasms, Castration-Resistant / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
C000610110:Pluvicto; D004151:Dipeptides; D006573:Heterocyclic Compounds, 1-Ring; D019275:Radiopharmaceuticals; D008187:Lutetium; D017430:Prostate-Specific Antigen